Neoadjuvant Pembrolizumab In Melanoma – EMJ
A promising new approach to treating desmoplastic melanoma, a rare and aggressive form of skin cancer, has demonstrated a significant positive response in a recent clinical trial. The phase 2 SWOG S1512 trial revealed that neoadjuvant pembrolizumab – treatment given before surgery – achieved a 71% pathological complete response rate in patients with surgically removable tumors.
Neoadjuvant Pembrolizumab and Desmoplastic Melanoma
The SWOG S1512 trial specifically evaluated the effectiveness of pembrolizumab, an anti-programmed cell death protein 1 therapy, in individuals diagnosed with desmoplastic melanoma. Researchers focused on the results observed after administering pembrolizumab before surgical removal of the tumor.
Twenty-eight patients with resectable desmoplastic melanoma participated in the study. Each patient received intravenous pembrolizumab at a dose of 200 mg every three weeks for three cycles prior to surgery. Tissue samples were analysed before treatment, during treatment (3-5 weeks after initiation), and after surgical removal.
Pathological Complete Response and Clinical Outcomes
The primary goal of the trial was to determine the pathological complete response rate, assessed by pathologists. The data showed a 71% rate, with a 95% confidence interval ranging from 51% to 87%. Investigators also monitored clinical response rate and overall survival as secondary measures.
Follow-up observations extended to three years, allowing for an initial assessment of longer-term outcomes in these patients.
Survival and Safety Findings
Over three years of follow-up, four participants had died. Importantly, none of these deaths were attributed to the melanoma itself or to adverse events related to the pembrolizumab treatment. The treatment was generally well-tolerated, with two patients (7% of the study population) experiencing grade 3 treatment-related adverse events. No other significant toxicities were reported.
The findings suggest that neoadjuvant pembrolizumab offers a high pathological complete response rate and an acceptable safety profile for patients with resectable desmoplastic melanoma. These results support further investigation into using programmed cell death protein 1 blockade as a pre-surgical treatment for this specific type of melanoma.
Frequently Asked Questions
What was the primary endpoint of the SWOG S1512 trial?
The primary endpoint was the pathological complete response rate by local pathological review.
How long did follow-up extend for patients in the study?
Follow up extended to three years, enabling preliminary evaluation of longer-term outcomes.
What percentage of patients experienced significant treatment-related adverse events?
Two patients, representing 7% of the study population, experienced grade 3 treatment related adverse events.
What role might immunotherapy play in the future of melanoma treatment, considering these findings?